Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Ki vehet részt

• Assessed by the investigator as having a refractory neuroimmune disease; Refractory neuroimmune diseases were defined as:
• Poor symptom control on at least three immunosuppressive agents for more than one year
• Clinical evidence of at least two relapses within 12 months or three relapses within 24 months and one relapse within 12 months prior to screening
• Male study participants must agree to use contraception during the treatment period for 1 year after receiving study treatment, and sperm donation is prohibited throughout the study period
• In the case of females with childbearing potential, need to agree to use contraception during the treatment period and for at least 1 year after receiving study treatment. Participants must have a negative serum pregnancy test result at screening and a confirmed negative urine pregnancy test result prior to first CART treatment

Ki nem vehet részt

• A history of drug or alcohol abuse within the 12 months prior to baseline, or any condition that in the opinion of the investigator is associated with poor adherence
• Women who are breastfeeding or pregnant, or who plan to become pregnant at any time during the 12-month time period following treatment with CART, or a history of spontaneous or induced abortion within 4 weeks prior to screening
• Study participants with a clinically relevant active infection (e.g., sepsis, pneumonia, or abscess) or serious infection (resulting in hospitalization or requiring antibiotic therapy) within 4 weeks prior to baseline
• The study participant has received a live attenuated vaccination within 8 weeks prior to baseline; or is scheduled to receive a live vaccination (including COVID-19 vaccine) within 8 weeks after treatment
• Study participants who have received prior treatment with rituximab within 6 months prior to baseline
• Study participants had received tolizumab, eculizumab within 3 months prior to baseline
• Study participants who have received intravenous human immunoglobulin, plasma exchange, undergone immunotherapy within 4 weeks prior to baseline
• Receiving blood transfusion therapy 4 weeks prior to baseline or during the screening period
• Any medical or psychiatric condition that, in the opinion of the investigator, may jeopardize the study participant or affect the study participant's ability to participate in this study
• Comorbid mental illness, suicidal ideation (affirmative answer (yes) to question 4 or question 5 of the Colombian Suicide Severity Rating Scale (C-SSRS) indicating a suicide attempt within the last 6 months)
• Presence of a history of tuberculosis infection, high risk of acquired tuberculosis infection
• known immunodeficiency diseases, including human immunodeficiency virus (HIV) infection
• Viral hepatitis B surface antigen (HBsAg) positivity during the screening period
• Any other condition that the investigator deems inappropriate for participation in the study
• Known concomitant serious underlying diseases, such as hepatic and renal impairment, hematologic disorders, previous severe cardiovascular disease, severe hypertension, diabetes mellitus, poor control of blood pressure and blood glucose
• Any of the following laboratory abnormalities during the screening period (a repeat measurement may be taken during the screening period prior to randomization to confirm results); (1) Elevated liver enzymes: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (ULN); (2) Total bilirubin > 1.5 times the ULN; (3) Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2; (4) CD19 + B cell count <40 cells/µL